A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
NCT ID: NCT05584670
Last Updated: 2025-12-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
542 participants
INTERVENTIONAL
2022-11-29
2028-06-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study will include 2 parts:
A dose escalation Part 1: for finding the therapeutic dose(s) of SAR445877 in a monotherapy given every 2 weeks (Q2W) or weekly (QW) and in combination with other anticancer therapies when applicable.
A multicohort dose expansion/dose optimization Part 2: for the assessment of safety and preliminary efficacy of SAR445877 in monotherapy and in combination with cetuximab or with next generation aCTLA4 (ADG126) or with bevacizumab. 2 recommended doses for expansion/optimization of SAR445877 identified from dose escalation part 1 will be tested in different indications in monotherapy and in combination with other anticancer therapies as applicable.
Approximately 542 participants will be exposed to the study intervention:
* approximately 123 participants in part 1,
* up to 410 participants in expansion/dose optimization part (part 2)
* and up to 9 participants in Japan cohort F.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Screening Period: up to 28 days
* Treatment Period: enrolled and exposed participants will receive continuous treatment until progressive disease (PD), or an occurrence of an unacceptable AE, a withdrawal of consent, or until other permanent discontinuation criteria described in the protocol are met.
The End of Treatment (EOT) visit will occur 30 days ±7 days from the last IMP administration or prior to the initiation of further therapy, whichever occurs first.
The follow-up period will occur until disease progression, the start of new anticancer therapy, death, or withdrawal of participant's consent, whichever comes first.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SAR445877 Expansion/Optimization Phase Cohort H1 (Part 2D)
SAR445877 will be administered intravenously in combination with bevacizumab in participants with advanced unresectable or metastatic CRC.
SAR445877
Concentrate for solution for infusion
Bevacizumab
Solution for infusion
SAR445877 Expansion/Optimization Phase Cohort H2 (Part 2D)
SAR445877 will be administered intravenously in combination with bevacizumab in participants with advanced unresectable or metastatic CRC.
SAR445877
Concentrate for solution for infusion
Bevacizumab
Solution for infusion
SAR445877 Escalation Phase (Part 1A)
SAR445877 monotherapy will be administered intravenously in participants with solid tumors over a 14-day cycle.
SAR445877
Concentrate for solution for infusion
SAR445877 Escalation Phase (Part1B)
SAR445877 will be administered intravenously in combination with ADG126 in participants with advanced unresectable or metastatic melanoma, non-small cell lung cancer (NSCLC); renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), colorectal cancer (MSIH/dMMR), malignant pleural mesothelioma or esophageal squamous cell carcinoma (ESCC).
SAR445877
Concentrate for solution for infusion
ADG126
Solution for infusion
SAR445877 Escalation Phase (Part 1C)
SAR445877 will be administered intravenously in combination with bevacizumab in participants with metastatic colorectal cancer (CRC).
SAR445877
Concentrate for solution for infusion
Bevacizumab
Solution for infusion
SAR445877 Expansion/Optimization Phase: Cohort A1 (Part 2A)
SAR445877 monotherapy will be administered intravenously (IV) in participants with non-small cell lung cancer (NSCLC).
SAR445877
Concentrate for solution for infusion
SAR445877 Expansion/Optimization Phase: Cohort A2 (Part 2A)
SAR445877 monotherapy will be administered intravenously (IV) in participants with non-small cell lung cancer (NSCLC).
SAR445877
Concentrate for solution for infusion
SAR445877 Expansion/Optimization Phase: Cohort B (Part 2A)
SAR445877 monotherapy will be administered intravenously in participants with hepatocellular carcinoma (HCC).
SAR445877
Concentrate for solution for infusion
SAR445877 Expansion/Optimization Phase: Cohort C1 (Part 2A)
SAR445877 monotherapy will be administered intravenously in participants with gastric cancer/gastro esophageal junction adenocarcinoma (GC/GEJ).
SAR445877
Concentrate for solution for infusion
SAR445877 Expansion/Optimization Phase: Cohort C2 (Part 2A)
SAR445877 monotherapy will be administered intravenously in participants with gastric cancer/gastro esophageal junction adenocarcinoma (GC/GEJ).
SAR445877
Concentrate for solution for infusion
SAR445877 Expansion/Optimization Phase: Cohort D (Part 2A)
SAR445877 monotherapy will be administered intravenously IV in participants with immune infiltrated tumor type.
SAR445877
Concentrate for solution for infusion
SAR445877 Expansion/Optimization Phase: Cohort E1 (Part 2B)
SAR445877 monotherapy will be administered intravenously in participants with colorectal cancer (CRC).
SAR445877
Concentrate for solution for infusion
SAR445877 Expansion/optimization Phase: Cohort E2 (Part 2A)
SAR445877 monotherapy will be administered intravenously in participants with colorectal cancer (CRC).
SAR445877
Concentrate for solution for infusion
SAR445877 Expansion/optimization Phase: Cohort E3 (Part 2B)
SAR445877 will be administered intravenously in combination with cetuximab in participants with colorectal cancer.
SAR445877
Concentrate for solution for infusion
Cetuximab
Solution for infusion
SAR445877 Japan Cohort F
SAR445877 monotherapy will be administered intravenously in participants with advanced unresectable or metastatic solid tumor, from Japan.
SAR445877
Concentrate for solution for infusion
SAR445877 Expansion/Optimization Phase Cohort G1 (Part 2C)
SAR445877 will be administered intravenously in combination with ADG126 in participants with metastatic melanoma.
SAR445877
Concentrate for solution for infusion
ADG126
Solution for infusion
SAR445877 Expansion/Optimization Phase Cohort G2 (Part 2C)
SAR445877 will be administered intravenously in combination with ADG126 in participants with metastatic melanoma.
SAR445877
Concentrate for solution for infusion
ADG126
Solution for infusion
SAR445877 Expansion/Optimization Phase Cohort G3 (Part 2C)
The Standard of Care (nivolumab and ipilimumab) will be administered intravenously in participants with metastatic melanoma.
Nivolumab
Solution for infusion
Ipilimumab
Solution for infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SAR445877
Concentrate for solution for infusion
Cetuximab
Solution for infusion
ADG126
Solution for infusion
Bevacizumab
Solution for infusion
Nivolumab
Solution for infusion
Ipilimumab
Solution for infusion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants with advanced unresectable or metastatic solid tumors for which, in the judgement of the investigator, no standard alternative therapy is available or is not in the best interest of the participant
2. Dose escalation Part 1B
* Participants with advanced unresectable or metastatic melanoma, NSCLC; renal cell carcinoma (RCC); HCC, colorectal cancer (MSI-H/dMMR), malignant pleural mesothelioma or esophageal squamous cell carcinoma (ESCC). and for who, in the judgement of the investigator, no standard alternative therapy is available or is not in the best interest of the participant.
3. Dose escalation Part 1C
* Histologically or cytologically confirmed diagnosis of advanced unresectable or metastatic colorectal cancer
* Participants with RAS-mutant and BRAF-mutant colorectal cancer are eligible for enrollment.
4. Dose expansion/optimization Part 2
Cancer diagnosis:
* Participants in Cohorts A1 and A2 (Part 2A): Histologically or cytologically confirmed diagnosis of metastatic non-small cell lung cancer (NSCLC)
* Participants in Cohort B (part 2A): Histologically or cytologically confirmed diagnosis of advanced unresectable or metastatic hepatocellular carcinoma (HCC), or clinically by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic participants (participants without cirrhosis must have had histological confirmation of diagnosis)
* Participants in Cohorts C1 and C2 (part 2A):
* Histologically or cytologically confirmed diagnosis of advanced unresectable or metastatic gastric cancer (GC) or Siewert Type 2 \& 3 gastro esophageal junction (GEJ) adenocarcinoma
* Disease with any CPS scoring. No need for CPS determination at local laboratory
* Participants must have MSI (metastatic microsatellite instability) or MMR (mismatch repair) status known or determined locally and must have non-MSI-H or proficient MMR (pMMR) disease to be eligible.
* Participants with unknown HER2/neu status must have their HER2/neu status determined locally. Participants with HER2/neu negative are eligible. Participants with HER2/neu positive tumors must have documentation of disease progression on treatment containing an approved HER2 targeted therapy to be eligible.
* Participants in Part 2A Cohorts E1 and E2, Part 2B Cohort E3 and Part 2D Cohorts H1 and H2: Histologically or cytologically confirmed diagnosis of advanced unresectable or metastatic colorectal cancer.
* Participants in Part 2A Cohorts E1, and E2 and Part 2B Cohort E3 MSI status:
Participants must have MSI status known or determined locally and must have non- MSI-H disease to be eligible.
* Participants in Part 2A Cohorts E1, E2, Part 2B Cohort E3 and Part 2D Cohorts H1 and H2: Participants with RAS-mutant and BRAF-mutant colorectal cancer are eligible for enrollment.
* Part 2C Cohorts G1, G2 and G3: Participants with histologically confirmed unresectable locally advanced or metastatic melanoma
5. Prior anticancer therapy (For dose expansion/optimization Part 2 only)
* Participants in Cohorts A1 and A2: Participants must have received at least 1 systemic therapy for the metastatic setting and must not be amenable to the available SOC.
* Participants in Cohort B: Participants who have received at least 1 prior anticancer therapy, including an anti-PD1/PD-L1 containing regimen, and for whom have progressed after a primary or secondary resistance to an anti-PD1/PD-L1.
* Participants in Cohorts C1 and C2: Participants should have failed or relapsed after at least 1 prior line of treatment which may or may not include an anti-PD1/PD-L1-based treatment depending on local standard of care.
* Participants in Cohort D: Participants must have received at least 1 systemic therapy for their advanced/ metastatic setting and must not be amenable to the available SOC.
* Participants in Part 2A Cohorts E1 and E2 and Part 2D Cohorts H1 and H2 should have failed or relapsed on at least 2 prior regimens.
* Participants in cohort E3 should have failed or relapsed on at least 1 prior regimen. Participants who have received cetuximab or other anti-EGFR therapy as part of their prior line of treatment are eligible.
* Part 2C Cohorts G1, G2 and G3: Participants must have received at least one prior line of therapy for advanced/metastatic melanoma and/or does not have any standard of care (SoC) treatment option or decline or is intolerant to be treated with SoC treatment.
Measurable Disease:
* At least 1 measurable lesion per RECIST 1.1 criteria
Part 1C and Part 2D: Adequate coagulation function for all participants. For participants receiving anti-coagulant therapy (except platelet anti-aggregates) the adequate therapeutic levels of INR should be confirmed.
Capable of giving signed informed consent.
Exclusion Criteria
* Predicted life expectancy ≤3 months
* For participants with HCC- Cohort B (Part 2): Child Pugh Class B or C liver score. Participants with Child Pugh Class B-7 score are allowed for Part 1.
* Diagnosed of any other malignancies, either progressing or requiring active treatments, within 2 years prior to enrollment
* Known active brain metastases or leptomeningeal metastases
* History of treatment-related immune-mediated (or immune-related) AEs from immune-modulatory agents (including but not limited to anti-PD1/PD-L1 agents and anti-cytotoxic T lymphocyte associated protein 4 monoclonal antibodies) that caused permanent discontinuation of the agent, or that were Grade 4 in severity or have not resolved to Grade ≤1
* Has any condition requiring ongoing/continuous corticosteroid therapy (\>10 mg prednisone/day or an anti-inflammatory equivalent) within 1 week prior to the first dose of the study medicine
* Any clinically significant cardiac (including valvular) or vascular (thromboembolic disorders) disease, within 6 months prior to the first IMP administration
* Ongoing or recent (within 2 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for immune-related adverse events
* Has a known history or any evidence of interstitial lung disease or active, non-infectious pneumonitis within 3 years prior to the first dose of the study drug.
* Organ transplant requiring immunosuppressive treatment
* Uncontrolled or active infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection, or has a diagnosis of immunodeficiency
The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanofi
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Sciences & Operations
Role: STUDY_DIRECTOR
Sanofi
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Christiana Care Health System- Site Number : 8400011
Newark, Delaware, United States
University of Iowa- Site Number : 8400014
Iowa City, Iowa, United States
University of Kansas Cancer Center Clinical Research Center (Fairway) Site Number : 8400008
Fairway, Kansas, United States
Barbara Ann Karmanos Cancer Institute - Detroit- Site Number : 8400006
Detroit, Michigan, United States
John Theurer Cancer Center Site Number : 8400001
Hackensack, New Jersey, United States
NYU Langone Medical Center-New York- 550 1st Ave - BRANY - PPDS- Site Number : 8400013
New York, New York, United States
Rhode Island Hospital Site Number : 8400004
Providence, Rhode Island, United States
University of Texas MD Anderson Cancer Center Site Number : 8400005
Houston, Texas, United States
Fred Hutchinson Cancer Center - 825 Eastlake Ave E- Site Number : 8400010
Seattle, Washington, United States
Servicios Médicos URUMED SpA_Investigational Site Number : 1520002
Rancagua, General Bernardo O'Higgins, Chile
BIOCINETIC Ltda_Investigational Site Number : 1520008
Santiago, Reg Metropolitana de Santiago, Chile
Fundacion Arturo Lopez Perez (FALP) - Providencia - Jose Manuel Infante 805_Investigational Site Number : 1520007
Providencia, , Chile
Centro de Investigacion Clinica Bradford Hill_Investigational Site Number : 1520004
Recoleta, , Chile
Hadassah Medical Center - PPDS_Investigational Site Number : 3760005
Jerusalem, Jerusalem, Israel
Shamir Medical Center_Investigational Site Number : 3760004
Be’er Ya‘aqov, , Israel
Sheba Medical Center - PPDS_Investigational Site Number : 3760003
Ramat Gan, , Israel
Tel Aviv Sourasky Medical Center Ichilov - PPDS_Investigational Site Number : 3760001
Tel Aviv, , Israel
Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis_Investigational Site Number : 5280001
Amsterdam, North Holland, Netherlands
Erasmus MC_Investigational Site Number : 5280003
Rotterdam, South Holland, Netherlands
Instituto de Investigacion Oncologica Vall d'Hebron (VHIO) - EPON_Investigational Site Number : 7240007
Barcelona, , Spain
START MADRID_Hospital Universitario HM Sanchinarro - CIOCC_Investigational Site Number : 7240005
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Trial Transparency email recommended (Toll free for US & Canada)
Role: CONTACT
Phone: 800-633-1610
Email: [email protected]
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jamal Misleh
Role: primary
Muhammad Furquan
Role: primary
Lisa Bogart
Role: primary
Ammar Sukari
Role: primary
Suzanne Kosky
Role: primary
Paul Oberstein
Role: primary
Kaitlyn Krar
Role: primary
Aung Naing
Role: primary
Elena Chiorean
Role: primary
Plinio Fernandez
Role: primary
Nicolas Obando Martínez
Role: primary
Christian Caglevic Medina
Role: primary
Carlos Ignacio Rojas Garcia
Role: primary
Jonathan Cohen
Role: primary
Carmell Fink
Role: primary
Tamar Beller
Role: primary
Ravit Geva
Role: primary
Marloes van Dongen
Role: primary
Ferry Eskens
Role: primary
Elena Garralda
Role: primary
Emiliano Calvo
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
TCD17620 Plain Language Results Summary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1277-4827
Identifier Type: REGISTRY
Identifier Source: secondary_id
2023-507141-28
Identifier Type: REGISTRY
Identifier Source: secondary_id
2022-001239-95
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
TCD17620
Identifier Type: -
Identifier Source: org_study_id